Sarepta Therapeutics, Inc. (SRPT)
23.77
+6.16
(+34.98%)
USD |
NASDAQ |
Mar 25, 16:00
23.40
-0.37
(-1.56%)
Pre-Market: 09:27
Sarepta Therapeutics Cash from Investing (Quarterly) : 96.21M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Keros Therapeutics, Inc. | -0.134M |
| Merck & Co., Inc. | -11.20B |
| PTC Therapeutics, Inc. | 34.01M |
| REGENXBIO, Inc. | 37.54M |
| Gilead Sciences, Inc. | -1.835B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 126.93M |
| Cash from Financing (Quarterly) | -34.94M |
| Free Cash Flow | -332.39M |
| Free Cash Flow Per Share (Quarterly) | 1.176 |
| Free Cash Flow to Equity (Quarterly) | 333.84M |
| Free Cash Flow to Firm (Quarterly) | 144.28M |
| Free Cash Flow Yield | -13.68% |